Ascletis Says PD-L1 Induces “Functional Cure” in CHB Patients
publication date: Jul 1, 2022
Hangzhou Ascletis Pharma reported that chronic hepatitis B patients experienced a “functional cure” after being treated with its PD-L1 antibody. In a Phase IIb clinical trial, 42.9% of chronic hepatitis B patients who received ASC22 (envafolimab) experienced a sustained HBsAg loss. In 2019, Ascletis acquired China rights to develop ASC22 for viral diseases from Suzhou Alphamab. The company has also started trials of the PD-L1 for HIV in China and the US. Ascletis’s initial project was Ganovo, an interferon-free therapy for hepatitis C virus, which was approved for China use in 2018. More details....
Stock Symbol: (HK: 1672)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.